Mission

NovaSterilis is committed to providing a new level of patient safety and product performance through the development of a new, emerging technology. The development of the supercritical carbon dioxide as a solvent for the NovaKill sterilent allows the biomedical community to achieve sterilization without compromising the product’s integrity. We have developed and preformed countless tests and experiments specifically designed to prove the existence of a Sterility Assurance Level of (SAL6) and the ease with which it is achieved. We are authorized to commercialize and sell this technology to various businesses including tissue bank processors.